These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 28984429)

  • 1. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens.
    Cozzi-Lepri A; Zangerle R; Machala L; Zilmer K; Ristola M; Pradier C; Kirk O; Sambatakou H; Fätkenheuer G; Yust I; Schmid P; Gottfredsson M; Khromova I; Jilich D; Flisiak R; Smidt J; Rozentale B; Radoi R; Losso MH; Lundgren JD; Mocroft A;
    HIV Med; 2018 Feb; 19(2):102-117. PubMed ID: 28984429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study.
    Pelchen-Matthews A; Larsen JF; Shepherd L; Begovac J; Pedersen K; De Wit S; Horban A; Jablonowska E; Johnson M; Khromova I; Losso MH; Nielsen LN; Ridolfo AL; Schmied B; Stephan C; Yust I; Curtis L; Vannappagari V; Ragone L; Roen A; Raben D; Kirk O; Peters L; Mocroft A;
    HIV Res Clin Pract; 2021 Dec; 22(6):160-168. PubMed ID: 34779362
    [No Abstract]   [Full Text] [Related]  

  • 3. Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
    Jiang J; Xu X; Guo W; Su J; Huang J; Liang B; Chen H; Zang N; Liao Y; Ye L; Liang H
    AIDS Res Ther; 2016; 13(1):30. PubMed ID: 27617024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and risk factors for invasive pneumococcal disease in HIV-infected and non-HIV-infected individuals before and after the introduction of combination antiretroviral therapy: persistent high risk among HIV-infected injecting drug users.
    Harboe ZB; Larsen MV; Ladelund S; Kronborg G; Konradsen HB; Gerstoft J; Larsen CS; Pedersen C; Pedersen G; Obel N; Benfield T
    Clin Infect Dis; 2014 Oct; 59(8):1168-76. PubMed ID: 25038114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real word outcomes associated with use of raltegravir in older people living with HIV: results from the 60 months follow-up of the RAL-age cohort.
    Santinelli L; Ceccarelli G; Borrazzo C; Celani L; Pavone P; Innocenti GP; Spagnolello O; Fimiani C; Ceci F; Di Sora F; Mezzaroma I; Mastroianni CM; d'Ettorre G
    Expert Rev Anti Infect Ther; 2020 May; 18(5):485-492. PubMed ID: 32096433
    [No Abstract]   [Full Text] [Related]  

  • 6. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study.
    Reynes J; Trinh R; Pulido F; Soto-Malave R; Gathe J; Qaqish R; Tian M; Fredrick L; Podsadecki T; Norton M; Nilius A
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):256-65. PubMed ID: 22730929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raltegravir use prospectively assessed in a major HIV outpatient clinic in Italy: sample population, virological-immunological activity, and tolerability profile.
    Manfredi R; Calza L; Marinacci G; Cascavilla A; Colangeli V; Salvadori C; Martelli G; Appolloni L; Puggioli C; Viale P
    Infez Med; 2014 Dec; 22(4):288-95. PubMed ID: 25551844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
    Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
    AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacokinetic profile of raltegravir-containing antiretroviral therapy in HIV-infected individuals over 60 years of age.
    Vera JH; Jackson A; Dickinson L; Else L; Barber T; Mora-Peris B; Back D; Boffito M; Winston A
    HIV Clin Trials; 2015; 16(1):39-42. PubMed ID: 25777188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
    Meditz AL; Palmer C; Predhomme J; Searls K; Kerr B; Seifert S; Caraway P; Gardner EM; MaWhinney S; Anderson PL
    AIDS Res Hum Retroviruses; 2015 Oct; 31(10):1015-22. PubMed ID: 26059647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?
    ; Mocroft A; Reiss P; Kirk O; Mussini C; Girardi E; Morlat P; Stephan C; De Wit S; Doerholt K; Ghosn J; Bucher HC; Lundgren JD; Chene G; Miro JM; Furrer H
    Clin Infect Dis; 2010 Sep; 51(5):611-9. PubMed ID: 20645862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of herpes zoster in HIV-infected adults in the combined antiretroviral therapy era: results from the FHDH-ANRS CO4 cohort.
    Grabar S; Tattevin P; Selinger-Leneman H; de La Blanchardiere A; de Truchis P; Rabaud C; Rey D; Daneluzzi V; Ferret S; Lascaux AS; Hanslik T; Costagliola D; Launay O;
    Clin Infect Dis; 2015 Apr; 60(8):1269-77. PubMed ID: 25601456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment.
    Lapadula G; Cozzi-Lepri A; Marchetti G; Antinori A; Chiodera A; Nicastri E; Parruti G; Galli M; Gori A; Monforte Ad;
    AIDS; 2013 Mar; 27(5):769-79. PubMed ID: 23719349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
    Taburet AM; Sauvageon H; Grinsztejn B; Assuied A; Veloso V; Pilotto JH; De Castro N; Grondin C; Fagard C; Molina JM
    Clin Infect Dis; 2015 Oct; 61(8):1328-35. PubMed ID: 26105170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch nationwide ATHENA cohort.
    Rokx C; Fibriani A; van de Vijver DA; Verbon A; Schutten M; Gras L; Rijnders BJ;
    Clin Infect Dis; 2015 Jan; 60(1):143-53. PubMed ID: 25273080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.
    Borges ÁH; Lundgren JD; Ridolfo A; Katlama C; Antunes F; Grzeszczuk A; Blaxhult A; Mitsura VM; Doroana M; Battegay M; Gargalianos P; Mocroft A;
    AIDS; 2014 Nov; 28(17):2565-71. PubMed ID: 25574959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
    Mocroft A; Ledergerber B; Zilmer K; Kirk O; Hirschel B; Viard JP; Reiss P; Francioli P; Lazzarin A; Machala L; Phillips AN; Lundgren JD;
    AIDS; 2007 Sep; 21(14):1867-75. PubMed ID: 17721094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients.
    Krikke M; Tesselaar K; van den Berk GEL; Otto SA; Freriks LH; van Lelyveld SFL; Visseren FJL; Hoepelman AIM; Arends JE
    HIV Clin Trials; 2018 Apr; 19(2):75-83. PubMed ID: 29770748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system.
    Horberg MA; Oakes AH; Hurley LB; Towner WJ; Chao CR; Silverberg MJ; Chantra JQ; Ellis CG; Quesenberry CP
    HIV Clin Trials; 2018 Oct; 19(5):177-187. PubMed ID: 30370835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.